RCUS
NYSE
$28.17
Arcus Biosciences Inc (RCUS)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $35.75 (+26.91%)
Market Cap
$3.52B
Free Cash Flow Yield
-13.91%
Beta (5Y)
1.50
Price Chart
Valuation
Market Cap$3.52B
P/S14.93
P/B6.80
Profitability
Total Revenue (TTM)$32M
Gross Profit (TTM)-$287M
EBITDA-$389M
Profit Margin-156.4%
Operating Margin-788%
EPS-$4.18
Financial Health
Debt-to-Equity19.1%
Free Cash Flow Yield-13.91%
Growth & Risk
EPS 5Y CAGR+14.36%
Revenue 5Y CAGR-17.88%
Beta (5Y)1.50
Sharpe Ratio2.02